Investors are buffeted through the Covid testing bonanza and the prospect of these, good for 90%+ of revenues, disappearing, with the tech selloff to boot.
This explains the extreme volatility of the shares as perspectives constantly change.
However, cutting through the fog it’s increasingly clear this company is a winner and will thrive post-Covid, and the shares aren’t all that expensive and could become cheaper still.
Looking for a portfolio of ideas like this one? Members of SHU Growth Portfolio get exclusive access to our model portfolio. Learn More »